A clinical-stage biotech developing pelareorep, an IV immunotherapy for breast, pancreatic, and anal cancers—essentially a virus engineered to train the immune system to attack tumors.
No revenue; annual net losses of CAD -0.02B to -0.03B. Money comes only from partnerships, like Roche supplying atezolizumab, not product sales.
Patents and clinical data on pelareorep create some protection, but larger rivals like Merck and Bristol Myers Squibb have deeper pockets and competing immunotherapies, making displacement feasible.
